ReWalk Robotics (NASDAQ:RWLK) Research Coverage Started at StockNews.com

ETFS

StockNews.com started coverage on shares of ReWalk Robotics (NASDAQ:RWLKGet Rating) in a research note issued on Sunday. The brokerage set a “sell” rating on the medical device company’s stock.

Separately, HC Wainwright lowered their price objective on shares of ReWalk Robotics from $3.50 to $2.50 and set a “buy” rating for the company in a research note on Wednesday, August 10th.


ReWalk Robotics Price Performance

NASDAQ:RWLK opened at $0.85 on Friday. ReWalk Robotics has a 1-year low of $0.80 and a 1-year high of $1.95. The company has a 50-day moving average of $0.96 and a 200 day moving average of $1.00. The firm has a market cap of $53.41 million, a PE ratio of -3.28 and a beta of 2.40.

ReWalk Robotics (NASDAQ:RWLKGet Rating) last released its quarterly earnings data on Tuesday, August 9th. The medical device company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.03). ReWalk Robotics had a negative return on equity of 17.60% and a negative net margin of 270.83%. The business had revenue of $1.57 million during the quarter, compared to analysts’ expectations of $2.32 million. During the same period last year, the company earned ($0.07) earnings per share. Sell-side analysts anticipate that ReWalk Robotics will post -0.27 EPS for the current fiscal year.

Insider Buying and Selling at ReWalk Robotics

In other news, major shareholder Global Fund Lp Lind II purchased 26,702 shares of the firm’s stock in a transaction on Friday, July 15th. The stock was acquired at an average cost of $1.02 per share, with a total value of $27,236.04. Following the completion of the transaction, the insider now owns 4,380,430 shares in the company, valued at approximately $4,468,038.60. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders bought 54,602 shares of company stock valued at $50,496. 0.78% of the stock is currently owned by insiders.

Institutional Trading of ReWalk Robotics

Several hedge funds have recently modified their holdings of RWLK. Advisor Group Holdings Inc. lifted its position in shares of ReWalk Robotics by 12.2% during the first quarter. Advisor Group Holdings Inc. now owns 1,038,207 shares of the medical device company’s stock valued at $1,204,000 after buying an additional 112,875 shares during the last quarter. Renaissance Technologies LLC acquired a new position in shares of ReWalk Robotics during the first quarter valued at about $35,000. Finally, Millennium Management LLC increased its holdings in shares of ReWalk Robotics by 78.6% during the second quarter. Millennium Management LLC now owns 138,282 shares of the medical device company’s stock valued at $130,000 after acquiring an additional 60,859 shares in the last quarter. 4.98% of the stock is owned by hedge funds and other institutional investors.

ReWalk Robotics Company Profile

(Get Rating)

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic.

Read More

Receive News & Ratings for ReWalk Robotics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ReWalk Robotics and related companies with MarketBeat.com’s FREE daily email newsletter.




Products You May Like